A pediatric study of Durasert three-year treatment for posterior segment uveitis.
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Posterior uveitis
- Focus Therapeutic Use
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.
- 13 Feb 2017 New trial record
- 07 Feb 2017 According to a pSivida media release, the Company is in discussions with the European regulatory authority on the final design of this trial and expects to file the application in the second quarter of calendar 2017.